BACKGROUND: Out-of-hospital cardiac arrest (OHCA) commonly presents with nonshockable rhythms (asystole and pulseless electric activity). It is unknown whether antiarrhythmic drugs are safe and effective when nonshockable rhythms evolve to shockable rhythms (ventricular fibrillation/pulseless ventricular tachycardia [VF/VT]) during resuscitation.
S
udden out-of-hospital cardiac arrest (OHCA) claims the lives of 347 000 persons each year in North America and hundreds of thousands more worldwide.
1, 2 The epidemiology of OHCA has changed over recent years, such that nonshockable rhythms (bradyasystole and pulseless electric activity [PEA] ) now predominate and are deemed to be largely nonsurvivable. [3] [4] [5] Nonshockable rhythms may evolve to shockable ventricular fibrillation or pulseless ventricular tachycardia (VF/VT) during the course of resuscitation in ≤25% of patients with OHCA, for whom antiarrhythmic drug use has both pragmatic and public health importance. 6, 7 Although antiarrhythmic medications are commonly administered for VF/VT, their specific role in treating nonshockable-turned-shockable rhythms has not been rigorously evaluated. Even if effective, their delayed deployment could prove too late to alter the clinical outcome from VF/VT that arises from a protracted period of asystole or PEA. Furthermore, the effects of antiarrhythmic drugs on conduction and tissue refractoriness could prove counterproductive were this to promote the recrudescence of bradyarrhythmias or PEA that originally provoked or accompanied OHCA or result in other harmful effects. Conversely, effective pharmacological suppression of recalcitrant VF/VT could help restore and stabilize circulation and in turn improve outcome. In short, the optimal approach to such patients is unknown.
The ALPS (Amiodarone, Lidocaine, or Placebo Study) was a prospective, randomized, double-blind, placebo-controlled multicenter trial evaluating the effectiveness of amiodarone and lidocaine for OHCA because of shock-resistant VF/VT. 8 Although the trial's main focus was on patients whose initial presenting OHCA rhythm was VF/VT, in actuality those patients with shock-resistant VF/VT at any time during resuscitation were eligible for randomization. 9 Thus, by design, the trial randomized 2 cohorts: those with initial VF/VT (previously reported) and the complementary group with initially nonshockable OHCA arrhythmias (asystole or PEA) that subsequently turned shockable during the course of resuscitation. Accordingly, we undertook a prespecified investigation of the clinical effects of amiodarone or lidocaine compared to placebo in the randomized cohort with initial nonshockableturned-shockable OHCA. The primary outcome was survival to hospital discharge; secondary outcomes included functional status at discharge and adverse drug-related effects.
METHODS

Patients
The background, methods, and primary outcome of the ALPS trial were previously described. 8, 9 This trial was conducted in compliance with all applicable regulatory requirements for exception from informed consent in emergency research. It involved paramedics from 55 emergency medical services (EMS) agencies across 10 North American sites participating in the Resuscitation Outcomes Consortium. 10 The trial enrolled patients ≥18 years of age with atraumatic OHCA, established intravenous or intraosseous vascular access, and persistent (nonterminating) or recurrent (restarting after successful termination) VF/VT after ≥1 shocks. Patients were randomized to licensed parenteral preparations of lidocaine, normal saline, or a captisol-based formulation of amiodarone (Nexterone, Baxter Healthcare). Protected populations; patients who had already received open-label intravenous amiodarone or lidocaine during resuscitation, who had known hypersensitivity to these drugs, or who had advanced directives (do not resuscitate orders); or in whom VF/VT terminated before study drug could be administered were excluded from the trial.
Clinical Perspective
What Is New?
• Out-of-hospital cardiac arrest (OHCA) claims hundreds of thousands of lives each year.
• Although historically OHCA commonly presented with ventricular fibrillation or pulseless ventricular tachycardia, it is now more often seen with nonshockable rhythms (asystole, pulseless electric activity).
• These rhythms can evolve to shock-refractory ventricular fibrillation or pulseless ventricular tachycardia during resuscitation in ≈25% of patients, for whom the effectiveness of antiarrhythmic drugs is unknown.
• This trial prospectively randomized 1063 such patients to amiodarone, lidocaine, or a placebo.
• A statistically insignificant trend toward better survival was found in drug than placebo recipients without increased risk of adverse events or neurological disability.
What Are the Clinical Implications?
• OHCA because of nonshockable rhythms is poor but not invariably fatal.
• When nonshockable OHCA turns shockable, absolute differences in survival in response to lidocaine or amiodarone as compared with placebo are consistent with the favorable trends in response to these drugs seen among patients in whom OHCA is caused by initial ventricular fibrillation or pulseless ventricular tachycardia.
• Taken together, these findings, although not definitive, may signal a clinical benefit from antiarrhythmic medications when shock-refractory ventricular fibrillation arises at any time and from any OHCA rhythm during the course of resuscitation.
• The role of antiarrhythmic drugs in shock-refractory OHCA invites further investigation.
ORIGINAL RESEARCH ARTICLE
The trial protocol specified that only patients who met clinical eligibility criteria and received any dose of study drug for ongoing shock-refractory VF/VT at any time during the resuscitation would be included in the analysis. Outcomes in the primary analysis population (composed of study-eligible drug recipients with confirmed VF/VT as the presenting cause of OHCA) and in all randomized patients by intention to treat (regardless of whether study eligible or having received drug) were previously reported, along with a listing of all participating EMS agencies and personnel. 8 The focus of the current study, the population of randomized study-eligible drug recipients whose initial OHCA was nonshockable but subsequently developed shock-refractory VF/VT, has not been previously characterized.
Definitions
Rhythms were identified from defibrillator recordings using cutaneous defibrillator electrodes that approximated a lead II configuration and were later reviewed manually by trained study personnel. A shockable versus nonshockable initial rhythm was determined by a shock versus no-shock advisory from an automated external defibrillator or by manual review of the electronic recording. PEA was defined as any organized ventricular rhythm (exclusive of ventricular tachycardia) with an absent pulse, asystole by absence of any ventricular rhythm or at most a single ventricular complex over a 6-second interval. VF was defined as irregular, disorganized ventricular electric activity of variable amplitude and ventricular tachycardia as an organized rhythm with a wide QRS interval (≥120 ms) without associated P waves at a rate of >150 beats per minute. The incident call was defined as the initial contact with the Public Safety Answering Point, which served as the emergency call center in each locality and represented the initial activation of EMS for the OHCA event. The incident call to EMS arrival was defined as the time interval from this call to the first arriving EMS vehicle at the street address of the OHCA event.
Design and Intervention
Trial drugs were packaged in sealed kits, each holding 3 identically formulated syringes of study drug, and each syringe containing 150 mg of amiodarone, 60 mg of lidocaine, or normal saline. Amiodarone, lidocaine, and normal saline (placebo) kits and respective syringes were indistinguishable except by a numeric code and were randomly distributed to EMS providers in equal ratios of 1:1:1. Randomization was stratified by participating Resuscitation Outcomes Consortium site and EMS agency in permuted blocks of concealed size.
Patients were treated in accordance with local EMS protocols and American Heart Association Advanced Life Support Guidelines in place at the time of the trial's conduct. 11 The subsequent opening of a study kit by EMS personnel constituted a patient's enrollment in the trial, whose masked contents (amiodarone, lidocaine, or placebo) determined his or her randomized treatment assignment. Two syringes were initially administered as a rapid bolus (1 syringe if the estimated body weight was <100 pounds [45 kg]), followed by standard resuscitation measures and shock(s). If VF/VT persisted, then a single supplemental syringe of the same assigned study drug was administered, followed by standard interventions according to local practice, exclusive of any open-label amiodarone or lidocaine before hospitalization.
All trial interventions were completed before patients' hospital arrival. Hospital care providers were informed about the trial but not treatment assignment unless emergency unblinding was requested, in which case it was provided strictly to the treating physician. Hospital care was not standardized, although its components were monitored.
Outcomes
The primary outcome of the trial was survival to hospital discharge. The secondary outcome was survival to discharge with favorable neurological functional status, defined on the modified Rankin scale (mRS) (ranging from 0, no symptoms, to 6, death) as ≤3, meaning being able to conduct activities of daily living independently or with minimal assistance, 12 and adverse drug-related effects. These effects were defined as those previously reported with these medications that occurred within 24 hours of their administration, including anaphylaxis, thrombophlebitis requiring treatment, clinical seizures, and bradycardia requiring temporary cardiac pacing. Other prespecified mechanistic outcomes included return of spontaneous circulation, survival to hospital admission, and responses to treatment (number of shocks and need for ancillary therapies).
Statistics
The previously reported primary analysis trial was powered to detect an absolute improvement of 6% in survival to hospital discharge from amiodarone versus placebo among treatment recipients with OHCA because of initial VF/VT; differences between lidocaine versus placebo and amiodarone versus lidocaine were secondary comparisons. 8 Although not its main focus, patients with late-occurring VF/VT were included in the trial for both pragmatic and scientific reasons. Pragmatically, the dynamic nature of cardiac rhythms during resuscitation made it infeasible to acutely discriminate early from later occurring VF/VT without giving confusing treatment directives to paramedic providers, which might only serve to impede patient care. Based on previous work, survival in this population was expected to be directionally similar to patients with OHCA because of initial VF/ VT but poor regardless of antiarrhythmic drug administration. 13, 14 Although recognized as underpowered, this analysis was prespecified to collect valuable information about the efficacy and safety of therapies that are often given under similar circumstances in clinical practice, which the trial was designed to represent. As such, finding a signal of potential benefit could serve to justify and inform more definitive future studies.
Because of potential imbalances in the characteristics between treatment arms in this population, we conducted multiple logistic regression to evaluate the trial's main end points of survival and neurological outcome at hospital discharge, adjusting for age, sex, arrest etiology (presumed cardiac versus not), arrest location (public versus private), bystander-or EMS-witnessed status of the OHCA, provision of bystander cardiopulmonary resuscitation (CPR), the incident call to EMS arrival interval, and trial site. Multiple imputation analysis (with 20 imputed data sets) was used to address any incomplete covariate data, using the mice package in R to minimize the potential bias of estimates compared with analyses limited to only cases with complete data. [15] [16] [17] Adjusted complete case analyses were also performed as an added sensitivity analysis of the imputation model. We tested for treatment differences according to the initial rhythm (PEA versus asystole) by adding an interaction term between the study arm and initial rhythm. P values were 2-sided, with statistical significance defined as an alpha of 0.05. Given the exploratory nature of the analyses, no adjustments were made for multiple comparisons.
The trial was approved by institutional review boards of all participating sites, with oversight by the US Food and Drug Administration and Health Canada and monitored by an independent data and safety board appointed by the National Heart, Lung, and Blood Institute. All the authors have read and approved the manuscript.
RESULTS
Patients
Enrollment for the trial began on May 7, 2012, and was completed on October 25, 2015. Of 37 889 patients with nontraumatic OHCA, 7903 had initial VF/VT (3026 of these were previously reported randomized recipients of study drug), and 29 986 had an initially nonshockable arrest rhythm, 1864 of whom subsequently developed VF/VT that was refractory to ≥1 shock(s) (Figure 1 ). Of these patients, 1320 were randomized to drug treatment, of whom 1063 with known treatment assignment remained study-eligible with ongoing episodes of VF/VT at time of treatment and constituted the primary analysis group for this study. In all, 389 patients received amiodarone, 358 patients received lidocaine, and 316 patients received placebo. Outcome was known in 1061 (99.8%), and 1032 (97%) had complete covariate data.
Among the 1063 randomized patients, the initial nonshockable OHCA rhythm was PEA in 400 (38%), asystole in 587 (55%), and not characterized in 76 (7%) patients. Patients (mean±SD) were 64.5±16.5 years of age, 70% were men, 44.7% had a bystander-witnessed OHCA, 14.7% occurred in a public location, and 46.1% received bystander CPR. The time from the incident call to EMS arrival (mean±SD) was 6.1±2.8 minutes, to first EMS shock 20.7±8.3 minutes, and to receipt of study drugs 26.9±8.9 minutes, which were administered after 2.2±1.1 shocks. These baseline and resuscitation event characteristics were generally balanced across active drug and placebo treatment arms, except for fewer men and a lower frequency of bystander CPR in the placebo arms among patients with initial PEA group and in the combined group with initially nonshockableturned-shockable rhythms (Table 1) .
Hospital Care
No significant differences in subsequent care were observed between treatment arms among patients who survived to hospital admission (Table 2 ). In the combined group of nonshockable-turned-shockable OHCA, ≥50% of hospitalized patients received targeted temperature management and early coronary catheterization. Life-sustaining therapies were limited or withdrawn in ≈30% of patients within the first 3 days after their OHCA and in ≈50% of patients overall.
Outcome
Unadjusted survival to hospital discharge among the 1061 of 1063 study-drug recipients with known outcome was 1.9% in the placebo arm, 3.1% in the lidocaine arm, and 4.1% in the amiodarone arm, and although reflecting 1.5-to 2-fold relative differences in outcome was not statistically significant (P=0.24) (Table 2). Patients who survived to hospital discharge had a mean mRS score of 3±2 (median 3), 52% of whom were discharged with an mRS ≤3 without significant differences between treatment arms (Table 3) . Among 1309 patients with known treatment assignment and outcome from the 1312 patients in the intention-totreat population (Figure 1 ), 19 of 466 of those randomized to amiodarone (4.1%), 15 of 440 to lidocaine (3.4%), and 13 of 403 to placebo (3.2%) survived to hospital discharge, which did not significantly differ among treatment groups. These differences were understandably attenuated by changes in patients' eligibility for drug treatment after initial randomization.
Adjusted Analyses
In multiple imputation-adjusted analyses of the combined group of randomized study drug-treated patients with an initial nonshockable-turned shockable OHCA, the absolute difference in survival to hospital discharge when treated with amiodarone versus placebo was 2.3% (95% confidence interval [CI], -0.3to 4.8%; P=0.08) and for lidocaine versus placebo was 1.2% (95% CI, -1.1 to 3.6; P=0.30). Similar relationships were observed for the secondary end point of survival with an mRS ≤3 in each of the case models and rhythm groups (Table 4) . Differences between amiodarone and lidocaine in any of these outcomes were not statistically significant (data not shown). Notably, the relationships between treatment arm and outcome were not different according to the initial rhythm (asystole or PEA) (P=0.87 test for interaction). In addition, no interaction was found between treatment arm and whether the initial OHCA rhythm was shockable (VF/VT) 8 or became shockable (nonshockable-turned-shockable) during the course of resuscita-tion on outcome (P=0.84 test for interaction). That is, from a survival perspective, whether the initial rhythm was asystole, PEA, or VF/VT did not significantly alter the response to antiarrhythmic treatment. Although not statistically different, survival trends all favored use of either antiarrhythmic agent (Figure 2 ).
Mechanistic Outcomes
After randomization, placebo recipients were more likely to require an additional blinded dose of study drug and a greater number of shocks than active drug (amiodarone or lidocaine) treatment arms (P<0.05) ( Table 2) . As an ancillary antiarrhythmic drug, magnesium was more commonly administered to patients in the placebo than active drug treatment arms in patients with initial asystole and in the combined nonshockable rhythm group (P<0.05). The use of vasopressin was infrequent and along with other resuscitation medications (bicarbonate, atropine, procainamide, and beta blockers) did not differ significantly among treatment arms in any of the rhythm groups. Epinephrine was administered to virtually all study patients who received a mean (±SD) cumulative dose of 5.6±2.6 mg that was similar across treatment arms (Table 2 ). In the combined group of nonshockable-turned-shockable OHCA, the likelihood of obtaining any return of spontaneous circulation (either transient or sustained) was lower among patients receiving amiodarone than in patients receiving lidocaine or placebo (31.5% versus 40.5% and 37.3% of patients, respectively; P=0.05). No significant differences were seen in the time interval from the incident call to initial (first) return of spontaneous circulation among the treatment groups (Table 3) . Similarly, the interval from the incident call to termination of resuscitation efforts among patients who were not transported to the hospital averaged (±SD) 45±10.7 minutes and did not differ significantly among treatment groups or by the presenting nonshockable rhythm. Unadjusted survival to hospital admission was significantly lower in patients receiving amiodarone than those receiving lidocaine and placebo across each of the initial nonshockable rhythm groups. In the combined group of nonshockable-turned-shockable OHCA, 64 (16.5%) patients receiving amiodarone versus 74 (20.7%) patients receiving lidocaine and 65 (20.6%) patients re- Out-of-hospital cardiac arrest was defined as the absence of consciousness and pulses that required cardiopulmonary resuscitation by emergency medical services (EMS) personnel. The criteria shown in the boxes corresponding to the "Ineligible 28 122" patients and the "Not enrolled 544" patients are listed in hierarchical fashion proceeding from the top to the bottom of each list. Thus, patients excluded (or not enrolled) for reasons shown higher on the list may have also met criteria shown lower on the list but were not duplicated in the numbers shown for these lower listed categories. IV indicates intravenous; and VF/VT, ventricular fibrillation or pulseless ventricular tachycardia. 
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Adverse Drug-Related Events
Adverse drug-related events, either overall or considered categorically (including thrombophlebitis, anaphylaxis, clinical seizures, and the need for temporary cardiac pacing within the first 24 hours of treatment) did not differ significantly in frequency between treatment arms in the initial nonshockable-turned-shockable rhythm group (Table 2) .
DISCUSSION
In this prospective, randomized trial, we found that outcome after nonshockable-turned-shockable OHCA was poor but not invariably fatal or neurologically devastating. Of the 33 survivors (3.1%), >50% had a favorable functional recovery at hospital discharge (mRS ≤3). Although the differences did not achieve statistical significance, patients treated with amiodarone or lidocaine experienced up to a doubling of survival over placebo without greater risk of adverse effects or functional disability. These findings were consistent with the trends toward better survival observed after active-drug treatment of patients who presented with an initial OHCA rhythm of VF/VT (Figure 2 ). 8 Taken together, these findings may signal a therapeutic benefit from amiodarone and lidocaine when shock-refractory VF/VT arises at any time or from any OHCA rhythm along the course of resuscitation.
Previous Studies
Compared with an initial rhythm of VF/VT, nonshockable OHCA because of asystole or PEA carries an ominous prognosis for which no treatment apart from high-quality CPR has yet proven to be effective. [18] [19] [20] [21] The comorbidities associated with nonshockable cardiac arrest, the lower treatment responsiveness of the rhythms themselves, and the circumstances under which the OHCA occurs may all contribute to this poor outcome. For example, compared with patients presenting with an initial VF/VT rhythm in the main study, 8 patients in the current study were older, were less likely to present with OHCA in a public setting, were less likely to be bystander-witnessed or receive bystander CPR, and had a longer interval from the incident call to EMS arrival, all factors associated with poor survival. 22, 23 Overall survival in this study fell in the same range reported by others when nonshockable OHCA evolves to VF/VT. 6, 24 Previous studies have variably observed prognosis to be improved, worsened, or indifferent to an arrhythmia's evolution from nonshockable to shockable depending on the clinical presentation. For example, survival was found to be better after conversion of a nonshockable rhythm to VF/VT when the antecedent rhythm was asystole rather than PEA, 25 if shock was administered sooner on its occurrence, 26 or in the context of a history of cardiovascular disease. 6 Others found no apparent association between outcome and patient or resuscitation characteristics, 27 or they suggested that worse outcomes might result from providers placing a greater emphasis on rhythm analysis and shock than on the greater need for uninterrupted CPR in such circumstances.
14 Because the use of antiarrhythmic medications was not reported in these studies, whether and how their administration might have contributed to these disparate findings and shaped the outcome of the patients are unknown. This issue has been largely unexplored until now.
Two previous randomized clinical trials of OHCA because of shock-refractory VF/VT also included patients in whom antiarrhythmic drugs were administered after conversion of initial asystole or PEA arrest to VF/VT. Unlike our findings, each reported numerically higher rates of hospital admission with amiodarone than with †P<0.05 among treatment arms within the described rhythm category. ‡The incident call was defined as the initial contact with the Public Safety Answering Point that served as the emergency call center in each locality and represented the initial activation of EMS for the out-of-hospital cardiac arrest (OHCA) event. The incident call to 1st EMS arrival was defined as the time interval from this call to the first arriving EMS vehicle at the street address of the OHCA event.
§Non-EMS-witnessed events. placebo (17% and 12%, respectively, among 83 patients with nonshockable-turned-shockable OHCA) 13 and with amiodarone than lidocaine (12% and 4%, respectively, among 61 patients) 28 but had no ultimate survivors in any of the treatment arms. By comparison, the lower rates of any return of spontaneous circulation and survival to hospital admission with amiodarone than with lidocaine or placebo observed in our study may signal a real effect, whereby amiodarone adversely affects return of circulation. Alternatively, the unadjusted relationships may be attributable to other confounding factors or to chance, given the number of EMS indicates emergency medical services; IO, intraosseous; IQR, interquartile range; and IV, intravenous. *P<0.05 among treatment arms within the described rhythm category. †Whether the listed prehospital drugs were administered was recorded in all randomized patients, with the exception of 1 patient in the lidocaine treatment arm for whom information about epinephrine administration was missing (and whose initial nonshockable rhythm diagnosis [asystole vs. pulseless electric activity] was also not known).
‡Not initiated before study drug given. §If the time of withdrawal of care was not recorded, then it was assumed to be >3 days. comparisons performed. It is important to note that although the prospect of harm was not entirely excluded, patients who received amiodarone in this study experienced no obvious worsening of survival to discharge, highlighting the potential challenge of drawing clinical inference from intermediate or surrogate outcomes in resuscitation research. Because treatment of late-occurring arrhythmias is invariably administered late, the resulting delay in restoring circulation may be another factor contributing to poor outcomes in this population. 29 In a previous report, survival only improved on conversion of asystole or PEA to VF/VT when the interval from the incident call to shock was ≤20 minutes. 26 In the current study, the time from the incident call to the first shock in the nonshockable-turned-shockable group averaged nearly 21 minutes, and nearly 27 minutes transpired before their receipt of study drug. This long interval and its consequence on the patient's physiology may have diluted a benefit from active drugs that might have occurred with earlier treatment.
Adverse Events
Because of conduction slowing and other rhythmsuppressive properties, it is possible that the administration of antiarrhythmic drugs for VF/VT, particularly in patients whose preceding rhythm was asystole or PEA, could theoretically lead to greater harm, including a recrudescence or worsening of bradyarrhythmias. Such adverse effects were not appreciated in this study because a significantly greater need for temporary pacing was not seen in the aftermath of drug treatment. Further, significant differences were not found in the incidence of other adverse drug-related events across the 3 treatment arms in this nonshockable-turned-shockable OHCA cohort (Table 2) . A greater need for temporary cardiac pacing in patients receiving amiodarone than lidocaine or a placebo was reported previously among patients with OHCA because of initial VF/VT, although the increment was relatively small. 
Limitations
This trial evaluated the risks and benefits of amiodarone and lidocaine (versus placebo) in a high-risk population in whom survival was expected to be poor regardless of treatment, and the study was intended to explore but was not robustly powered to prove clinical effects. We did not observe a statistically significant survival difference among the treatment arms. However, the consis- †Thirty-one patients were excluded because of missing survival status or missing covariates. ‡Two patients were excluded because of missing mRS. §Thirty-one patients were excluded because of missing values for mRS, covariates, or both.
tent trends toward improved survival could also be interpreted as potential signals of benefit from active-drug treatment. If amiodarone or lidocaine achieved a true absolute improvement in survival of 2% over placebo as seen in this study, then a trial of ≈3000 patients would be required to establish this benefit with 90% power. The trial was also not powered to make direct comparisons between the effectiveness of amiodarone and lidocaine. Thus, although point estimates and statistical trends tended to favor a stronger effect from amiodarone than lidocaine on survival, these differences do not necessarily imply the superiority of 1 drug over the other. Similarly, the absence of significant differences in the incidence of adverse drug-related effects across treatment arms does not completely preclude this possibility, although our findings indicate their overall frequency was low.
Comorbid conditions that might have contributed to OHCA and its outcome were not assessed in the study population, and although this study had a randomized design, we cannot confirm that treatment groups were balanced in all respects. In addition, hospital treatments, although monitored, were not controlled and might have influenced outcomes. Nevertheless, we did not observe differences in prognostic hospital treatments across the groups. The primary end point of the trial was survival to hospital discharge, which could be reliably ascertained in virtually all study patients. Although arguably more meaningful, 30-day or 1-year survival can be more challenging to obtain and, being less complete, potentially more subject to bias. These limitations should be balanced with the strengths of the study. The results were derived from a large population of patients with OHCA who were prospectively randomized in a double-blind trial design and systematically assessed, and involved analyses that accounted for important confounders.
Implications
Shock-refractory VF/VT as a primary or secondary event continues to be a frequently encountered arrhythmia during resuscitation. If ineffective, the added cost and needless distraction created by antiarrhythmic drugs such as amiodarone and lidocaine argues against their continued use in such patients. However, if effective, improving absolute survival by merely 2% in this patient population means >1000 additional lives might be saved each year in North America from nonshockableturned-shockable OHCA alone, many of whom will be functionally independent or require minimal assistance with daily living.
Conclusions
Outcome from nonshockable-turned shockable OHCA is poor but not invariably fatal. Although the differences were not statistically significant, point estimates for survival were higher among patients randomized to amiodarone or lidocaine than to a placebo, without increased risk of adverse drug-related effects or functional disability. These results are consistent with previously reported trends toward better survival from antiarrhythmic drug treatment when OHCA initially presents as shock-refractory VF/VT. Taken together, the findings may signal a clinical benefit from amiodarone or lidocaine when shock-refractory VF/VT arises at any time or from any OHCA rhythm along the course of resuscitation and invites further investigation. 8 and the present study of patients with nonshockableturned shockable cardiac arrest (adjusted using multiple imputation analyses). Survival was adjusted for baseline differences in the nonshockable-turned-shockable group, whereas these were balanced and not adjusted in the initial shockable group. CI indicates confidence interval; PEA, pulseless electric activity; and VF/VT, ventricular fibrillation or pulseless ventricular tachycardia. 
